Literature DB >> 30053153

Human Polyclonal Antibodies Produced by Transchromosomal Cattle Provide Partial Protection Against Lethal Zaire Ebolavirus Challenge in Rhesus Macaques.

Kyle Rosenke1, Callie E Bounds2, Patrick W Hanley3, Greg Saturday3, Eddie Sullivan4, Hua Wu4, Jin-An Jiao4, Heinz Feldmann1, Connie Schmaljohn5, David Safronetz1,6.   

Abstract

Antibody therapy has been used to treat a variety of diseases and the success of ZMapp and other monoclonal antibody-based therapies during the 2014-2016 West African Ebola outbreak has shown this countermeasure can be a successful therapy for Ebola hemorrhagic fever. This study utilized transchromosomal bovines (TcB) vaccinated with a DNA plasmid encoding Ebola virus glycoprotein sequence to produce human polyclonal antibodies directed against Ebola virus glycoprotein. When administered 1 day postinfection, these TcB polyclonal antibodies provided partial protection and resulted in a 50% survival rate following a lethal challenge of Ebola virus Makona in rhesus macaques.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30053153      PMCID： PMC6249563          DOI： 10.1093/infdis/jiy430

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  16 in total

1.  Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies.

Authors:  Xiangguo Qiu; Jonathan Audet; Gary Wong; Stephane Pillet; Alexander Bello; Teresa Cabral; Jim E Strong; Frank Plummer; Cindy R Corbett; Judie B Alimonti; Gary P Kobinger
Journal:  Sci Transl Med       Date:  2012-06-13       Impact factor: 17.956

2.  Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques.

Authors:  Gene Garrard Olinger; James Pettitt; Do Kim; Cara Working; Ognian Bohorov; Barry Bratcher; Ernie Hiatt; Steven D Hume; Ashley K Johnson; Josh Morton; Michael Pauly; Kevin J Whaley; Calli M Lear; Julia E Biggins; Corinne Scully; Lisa Hensley; Larry Zeitlin
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-15       Impact factor: 11.205

3.  Efficacy of Vesicular Stomatitis Virus-Ebola Virus Postexposure Treatment in Rhesus Macaques Infected With Ebola Virus Makona.

Authors:  Andrea Marzi; Patrick W Hanley; Elaine Haddock; Cynthia Martellaro; Gary Kobinger; Heinz Feldmann
Journal:  J Infect Dis       Date:  2016-08-05       Impact factor: 5.226

4.  Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever.

Authors:  Andrea Marzi; Reiko Yoshida; Hiroko Miyamoto; Mari Ishijima; Yasuhiko Suzuki; Megumi Higuchi; Yukie Matsuyama; Manabu Igarashi; Eri Nakayama; Makoto Kuroda; Masayuki Saijo; Friederike Feldmann; Douglas Brining; Heinz Feldmann; Ayato Takada
Journal:  PLoS One       Date:  2012-04-27       Impact factor: 3.240

5.  Human Polyclonal Antibodies Produced through DNA Vaccination of Transchromosomal Cattle Provide Mice with Post-Exposure Protection against Lethal Zaire and Sudan Ebolaviruses.

Authors:  Callie E Bounds; Steven A Kwilas; Ana I Kuehne; Jennifer M Brannan; Russell R Bakken; John M Dye; Jay W Hooper; Lesley C Dupuy; Barry Ellefsen; Drew Hannaman; Hua Wu; Jin-an Jiao; Eddie J Sullivan; Connie S Schmaljohn
Journal:  PLoS One       Date:  2015-09-30       Impact factor: 3.240

6.  Physiological level production of antigen-specific human immunoglobulin in cloned transchromosomic cattle.

Authors:  Akiko Sano; Hiroaki Matsushita; Hua Wu; Jin-An Jiao; Poothappillai Kasinathan; Eddie J Sullivan; Zhongde Wang; Yoshimi Kuroiwa
Journal:  PLoS One       Date:  2013-10-24       Impact factor: 3.240

7.  Triple immunoglobulin gene knockout transchromosomic cattle: bovine lambda cluster deletion and its effect on fully human polyclonal antibody production.

Authors:  Hiroaki Matsushita; Akiko Sano; Hua Wu; Jin-An Jiao; Poothappillai Kasinathan; Eddie J Sullivan; Zhongde Wang; Yoshimi Kuroiwa
Journal:  PLoS One       Date:  2014-03-06       Impact factor: 3.240

8.  Antibody therapies for the prevention and treatment of viral infections.

Authors:  Georgina Salazar; Ningyan Zhang; Tong-Ming Fu; Zhiqiang An
Journal:  NPJ Vaccines       Date:  2017-07-10       Impact factor: 7.344

9.  Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea.

Authors:  Johan van Griensven; Tansy Edwards; Xavier de Lamballerie; Malcolm G Semple; Pierre Gallian; Sylvain Baize; Peter W Horby; Hervé Raoul; N'Faly Magassouba; Annick Antierens; Carolyn Lomas; Ousmane Faye; Amadou A Sall; Katrien Fransen; Jozefien Buyze; Raffaella Ravinetto; Pierre Tiberghien; Yves Claeys; Maaike De Crop; Lutgarde Lynen; Elhadj Ibrahima Bah; Peter G Smith; Alexandre Delamou; Anja De Weggheleire; Nyankoye Haba
Journal:  N Engl J Med       Date:  2016-01-07       Impact factor: 91.245

10.  Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp.

Authors:  Xiangguo Qiu; Gary Wong; Jonathan Audet; Alexander Bello; Lisa Fernando; Judie B Alimonti; Hugues Fausther-Bovendo; Haiyan Wei; Jenna Aviles; Ernie Hiatt; Ashley Johnson; Josh Morton; Kelsi Swope; Ognian Bohorov; Natasha Bohorova; Charles Goodman; Do Kim; Michael H Pauly; Jesus Velasco; James Pettitt; Gene G Olinger; Kevin Whaley; Bianli Xu; James E Strong; Larry Zeitlin; Gary P Kobinger
Journal:  Nature       Date:  2014-08-29       Impact factor: 49.962
View more
  4 in total

Review 1.  Vaccines against Ebola virus and Marburg virus: recent advances and promising candidates.

Authors:  John J Suschak; Connie S Schmaljohn
Journal:  Hum Vaccin Immunother       Date:  2019-10-07       Impact factor: 3.452

Review 2.  Polyclonal hyper immunoglobulin: A proven treatment and prophylaxis platform for passive immunization to address existing and emerging diseases.

Authors:  Tharmala Tharmalingam; Xiaobing Han; Ashley Wozniak; Laura Saward
Journal:  Hum Vaccin Immunother       Date:  2021-05-19       Impact factor: 4.526

Review 3.  Transchromosomic bovines-derived broadly neutralizing antibodies as potent biotherapeutics to counter important emerging viral pathogens with a special focus on SARS-CoV-2, MERS-CoV, Ebola, Zika, HIV-1, and influenza A virus.

Authors:  AbdulRahman A Saied; Manuela Sales Lima Nascimento; Adriano Henrique do Nascimento Rangel; Krzysztof Skowron; Katarzyna Grudlewska-Buda; Kuldeep Dhama; Jaffer Shah; Ahmed Abdeen; Fouad S El-Mayet; Hassan Ahmed; Asmaa A Metwally
Journal:  J Med Virol       Date:  2022-06-11       Impact factor: 20.693

Review 4.  COVID-19: The Immune Responses and Clinical Therapy Candidates.

Authors:  Sareh Zhand; Marie Saghaeian Jazi; Saeed Mohammadi; Roozbeh Tarighati Rasekhi; Ghassem Rostamian; Mohammad Reza Kalani; Aida Rostamian; Jacob George; Mark W Douglas
Journal:  Int J Mol Sci       Date:  2020-08-03       Impact factor: 5.923
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.